Close

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

03 Mar 2010
Director/PDMR Shareholding

March 3, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on March 1, 2010 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (the “Plan”).

Awards of Stock Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMRType of SecurityNo of Ordinary Shares or ADSs Exercise price
Angus Russell (Executive Director)* ADSs 105,616 $64.91
Graham Hetherington (Executive Director)* Ordinary Shares 134,814 £14.43
Tatjana May Ordinary Shares 38,000 £14.43
Michael Cola ADSs20,000 $64.91
Sylvie Gregoire ADSs20,000 $64.91
Barbara Deptula ADSs 12,333 $64.91
Anita Graham ADSs 11,333 $64.91

*Vesting of awards to Executive Directors is subject to performance targets

SARs will normally vest after three years, subject to any performance targets having been satisfied. Vested SARs will be capable of exercise for a period of four years. The four year exercise period is subject to shareholder approval at Shire plc’s 2010 Annual General Meeting. Should such approval not be obtained, the exercise period will be two years. No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSA Awards”) under Part B of the Plan

Name of PDMRType of Security No of Ordinary Shares or ADSs Market value
Angus Russell (Executive Director)* ADSs73,948 $64.91
Graham Hetherington (Executive Director)* Ordinary Shares 98,864 £14.43
Tatjana May Ordinary Shares 28,000 £14.43
Michael Cola ADSs 15,000 $64.91
Sylvie Gregoire ADSs 15,000 $64.91
Barbara Deptula ADSs9,000 $64.91
Anita Graham ADSs 8,000 $64.91

*Vesting of awards to Executive Directors is subject to performance targets

The PSA Awards will normally vest after three years, subject to any performance targets being satisfied. Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days. No consideration was paid for the grant of the PSA Awards.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie
Deputy Company Secretary

For further information please contact:

Investor RelationsCléa Rosenfeld (Rest of the World)  +44 1256 894 160
 Eric Rojas (North America) +1 617 551 9715

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

03 Mar 2010 Director/PDMR Shareholding (40KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
equipment
to local
schools?